• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Y-mAbs Therapeutics Inc.

    5/30/25 4:13:09 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $YMAB alert in real time by email
    DEFA14A 1 ymab-20250530xdefa14a.htm DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

    ​

    ​

    Filed by the Registrant ⌧

    ​

    Filed by a Party other than the Registrant ◻

    ​

    Check the appropriate box:

    ◻

    Preliminary Proxy Statement

    ◻

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ◻

    Definitive Proxy Statement

    ⌧

    Definitive Additional Materials

    ◻

    Soliciting Material under §240.14a-12

    ​

    ​

    ​

    ​

    ​

    Y-MABS THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    ​

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    ​

    Payment of Filing Fee (Check the appropriate box):

    ⌧

    No fee required.

    ◻

    Fee paid previously with preliminary materials.

    ◻

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    ​

    ​


    GRAPHIC

    1. Election of Class I Director: David N. Gill 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. 3. To approve, on a non-binding advisory vote basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement. 4. To conduct any other business properly brought before the meeting or any adjournment or postponement thereof. THE BOARD RECOMMENDS A VOTE “FOR” THE ELECTION OF THE DIRECTOR NOMINEE, AND “FOR” ITEMS 2 AND 3. NOMINEE: This communication presents only an overview of the more complete proxy materials that are available to you on the Internet and is not a form for voting. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. If not requested, you will not receive a paper or e-mail copy of the proxy materials. To facilitate timely delivery please make the request as instructed below before 6/27/2025. Please visit http://www.astproxyportal.com/ast/22412, where the following materials are available for view: • Notice of Annual Meeting of Stockholders • Proxy Statement • Form of Electronic Proxy Card • Annual Report on Form 10-K TO REQUEST MATERIAL: TELEPHONE: 888-Proxy-NA (888-776-9962) or 201-299-6210 (for international callers) E-MAIL: [email protected] WEBSITE: https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials TO VOTE: ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the cut-off or meeting date. VIRTUALLY AT THE MEETING: The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit https://meetings.lumiconnect.com/200-405-049-174 (password: ymabs2025) and be sure to have available the 11-digit control number listed above or in your electronic proxy card. TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call. MAIL: You may request a card by following the instructions above. COMPANY NUMBER ACCOUNT NUMBER CONTROL NUMBER JOHN SMITH 1234 MAIN STREET APT. 203 NEW YORK, NY 10038 Please note that you cannot use this notice to vote by mail. Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting of Y-MABS THERAPEUTICS, INC. To Be Held On: July 11, 2025 at 8:00 a.m. Eastern Time For Stockholders of Record as of May 23, 2025 via the Internet at https://meetings.lumiconnect.com/200-405-049-174 (password: ymabs2025)

    Get the next $YMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $YMAB

    DatePrice TargetRatingAnalyst
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    11/18/2024$23.00Outperform
    Oppenheimer
    8/16/2024$20.00Overweight
    Cantor Fitzgerald
    6/28/2024$21.00Buy
    Truist
    5/10/2023$5.00 → $13.00Neutral → Outperform
    Wedbush
    4/3/2023Buy → Neutral
    Guggenheim
    1/27/2023$4.00Equal-Weight → Underweight
    Morgan Stanley
    1/5/2023Outperform → Market Perform
    Cowen
    More analyst ratings

    $YMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wg Biotech Aps bought $44,232 worth of shares (6,455 units at $6.85), increasing direct ownership by 0.14% to 4,559,233 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      12/12/23 8:27:16 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedell-Wedellsborg Johan bought $44,232 worth of shares (6,455 units at $6.85) (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      12/12/23 8:26:25 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wg Biotech Aps bought $40,190 worth of shares (6,183 units at $6.50) and bought $850,222 worth of shares (121,366 units at $7.01), increasing direct ownership by 3% to 4,552,778 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      12/11/23 5:25:50 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

      Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

      3/21/24 10:20:07 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Y-mAbs Therapeutics Inc.

      DEFA14A - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

      5/30/25 4:13:09 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Y-mAbs Therapeutics Inc.

      DEF 14A - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

      5/30/25 4:10:32 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

      5/28/25 7:04:45 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

      NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co

      1/10/25 7:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

      NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre

      7/1/24 4:05:00 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

      NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop

      6/5/24 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $YMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $YMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $YMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

      SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

      11/14/24 4:32:10 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

      SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

      11/12/24 6:00:40 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

      SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

      11/4/24 2:16:23 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Rossi Michael J sold $20,368 worth of shares (3,917 units at $5.20), decreasing direct ownership by 3% to 137,083 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      3/11/25 8:17:08 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF BUSINESS OFFICER Gad Thomas sold $56,536 worth of shares (10,810 units at $5.23), decreasing direct ownership by 5% to 202,721 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      3/11/25 8:15:41 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Pfreundschuh Peter P. was granted 31,800 shares, increasing direct ownership by 69% to 77,800 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      1/22/25 7:05:55 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

      Company's Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTAIncreased tumor retention and total tumor uptake anticipated by using optimized universal RadiohaptenCompany plans to initiate a Trial 1001 Bridge study (Part 2A) with optimized Radiohapten, "Proteus", in 1H 2026 with data readout in 2H 2026; Part B of Trial 1001 anticipated to initiate with Proteus in 1H 2027 with data readout in 2H 2027Expanded Radiopharmaceutical pipeline to focus on target franchise areas in oncology, with specific prog

      5/28/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

      PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic solid tumors known to express GD2 in a trial in progress poster at the Advances in Neuroblastoma Research Meeting ("ANR") being held on May 25-28, 2025 in Washington, D.C. The trial in progress poster titled "A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: 177Lu-DOTA in patients wit

      5/26/25 10:00:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

      PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will hold a virtual Radiopharmaceutical R&D update at 8:00 a.m. ET on Wednesday, May 28, 2025. During the virtual Radiopharmaceutical R&D update, Y-mAbs will discuss: Part A clinical data from the Company's ongoing Phase 1 GD2-SADA clinical trial (Trial 1001), including pharmacokinetic and dosimetry data; updates around the Company's nonclinical optimization studies

      5/13/25 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Y-mAbs Therapeutics from Neutral to Underperform and set a new price target of $3.00

      4/22/25 7:23:34 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Y-mAbs Therapeutics with a new price target

      Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00

      11/18/24 8:23:54 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Y-mAbs Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00

      8/16/24 7:40:36 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Financials

    Live finance-specific insights

    See more
    • Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

      Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®)Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201)The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025As of March 31, 2025, cash and cash equiv

      5/13/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

      PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, May 13, 2025 at 8:00 a.m. ET. A live audio webcast of the call will be available on the Investor Relations section of the Company's website at https://ir.ymabs.com/events-and-presentat

      5/6/25 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

      Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR

      3/4/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care